TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34969009

Group type: EXPERIMENTAL
Intervention: Unilateral Nordic Hamstring Exercise with a platform angle of 40° (N40U)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Unilateral Nordic Hamstring Exercise with a platform angle of 50° (N50U)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Bilateral Nordic Hamstring Exercise with a platform angle of 40° (N40)
Number of subjects: 14
Study: 32078096

Group type: EXPERIMENTAL
Intervention: Intracoronary tirofiban
Number of subjects: 208

Group type: COMPARATOR
Intervention: Intravenous tirofiban
Number of subjects: 208
Study: 34474487

Group type: EXPERIMENTAL
Intervention: Oxygen therapy (O2)
Number of subjects: 55000

Group type: EXPERIMENTAL
Intervention: Target oxygen saturation recommendations
Number of subjects: 55000
Study: 32920968

Group type: EXPERIMENTAL
Intervention: Robotic surgery (RG)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Laparoscopic surgery (LG)
Number of subjects: 116
Study: 35169036

Group type: COMPARATOR
Intervention: Iberdomide (0.3 mg every other day, 0.3 mg once daily, 0.6 mg and 0.3 mg alternating once daily, or 0.6 mg once daily)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Iberdomide
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 34393001

Group type: EXPERIMENTAL
Intervention: Personalized nutritional intervention program (individual, collective, and telephone recall)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Standard treatment (Control group)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Personalized nutritional intervention program
Number of subjects: 75
Study: 32819393

Group type: EXPERIMENTAL
Intervention: CAF3 (3-mg∙kg-1 of caffeine)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: CAF6 (6-mg∙kg-1 of caffeine)
Number of subjects: 20

Group type: COMPARATOR
Intervention: PLA (non-caffeinated placebo)
Number of subjects: 20

Group type: COMPARATOR
Intervention: CON (no supplement)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 20
Study: 35750730

Group type: EXPERIMENTAL
Intervention: Dental home visits (DHVs) every six months for 24 months
Number of subjects: 327

Group type: COMPARATOR
Intervention: Educational leaflets only (Control Group)
Number of subjects: 327
Study: 33560390

Group type: EXPERIMENTAL
Intervention: Fludarabine plus cytarabine (FLUGA)
Number of subjects: 283

Group type: COMPARATOR
Intervention: 5-azacitidine
Number of subjects: 283
Study: 35484921

Group type: EXPERIMENTAL
Intervention: Gong meditation (7 sessions, 50-60 minutes each)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 80
Study: 33895833

Group type: EXPERIMENTAL
Intervention: Weight-reduction intervention (group 1)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Usual care (group 2)
Number of subjects: 133
Study: 35869943

Group type: EXPERIMENTAL
Intervention: Immediate titrated intravenous oxytocin infusion and early amniotomy
Number of subjects: 232

Group type: COMPARATOR
Intervention: Delayed amniotomy after 4 hours of oxytocin
Number of subjects: 232
Study: 33430647

Group type: EXPERIMENTAL
Intervention: MFG delivery by parent peers
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: MFG delivery by School Health Education Program (SHEP) coordinators
Number of subjects: 180

Group type: COMPARATOR
Intervention: Intervention with mental health wellness materials and educational supports
Number of subjects: 180
Study: 35753926

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (4000 IU/day)
Number of subjects: 2423

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2423
Study: 34759152

Group type: EXPERIMENTAL
Intervention: Neutrophil gelatinase-associated lipocalin (NGL)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Neutrophil/Lymphocyte (N/L) ratio
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group (healthy pregnant women)
Number of subjects: 132
Study: 32061508

Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 35757837

Group type: EXPERIMENTAL
Intervention: Smart glasses
Number of subjects: 68

Group type: COMPARATOR
Intervention: Manual counting
Number of subjects: 68
Study: 33108442

Group type: EXPERIMENTAL
Intervention: Older anesthesiologists
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Female anesthesiologists
Number of subjects: 300
Study: 32293516

Group type: EXPERIMENTAL
Intervention: LifeSpan model (multicomponent, evidence‐based, system‐wide approach to suicide prevention) implemented over a 2-year period.
Number of subjects: 0
Study: 35561473

Group type: EXPERIMENTAL
Intervention: Resistance training for 12 weeks
Number of subjects: 23

Group type: COMPARATOR
Intervention: Healthy lifestyle recommendations (control)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 23
Study: 33230978

Group type: EXPERIMENTAL
Intervention: B‐PPM
Number of subjects: 30

Group type: COMPARATOR
Intervention: d‐PTFE
Number of subjects: 30
Study: 33938568

Group type: EXPERIMENTAL
Intervention: Group psychoeducation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 33750351

Group type: EXPERIMENTAL
Intervention: Adapted version of Problem Management Plus (PM+)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Enhanced treatment as usual (ETAU)
Number of subjects: 240
Study: 34242666

Group type: EXPERIMENTAL
Intervention: Reduced nicotine content cigarettes (0.4 mg, 2.4 mg, 15.8 mg nicotine/g tobacco)
Number of subjects: 775
Study: 34766245

Group type: EXPERIMENTAL
Intervention: Economic threat condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonthreatening control condition
Number of subjects: 0
Study: 33608058

Group type: EXPERIMENTAL
Intervention: IVIg and 1000 mg intravenous methylprednisolone (IVMP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: IVIg and placebo (sodium chloride 0.9%)
Number of subjects: 0
Study: 32627605

Group type: EXPERIMENTAL
Intervention: Cheonwangbosimdan
Number of subjects: 22

Group type: COMPARATOR
Intervention: Cognitive-Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 22
Study: 35817336

Group type: EXPERIMENTAL
Intervention: D 0.3 μg·kg−1·h−1 dexmedetomidine
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: D 0.4 μg·kg−1·h−1 dexmedetomidine
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: D 0.5 μg·kg−1·h−1 dexmedetomidine
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: D 0.6 μg·kg−1·h−1 dexmedetomidine
Number of subjects: 356

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 356
Study: 32993721

Group type: EXPERIMENTAL
Intervention: Foot orthoses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Corticosteroid injection
Number of subjects: 0
Study: 33734433

Group type: EXPERIMENTAL
Intervention: Standard-dose regimen (commencing at 25 μg)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Low-dose regimen (commencing at 12 μg)
Number of subjects: 262
Study: 32583013

Group type: EXPERIMENTAL
Intervention: 20 mg yohimbine
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: 40 mg yohimbine
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Controllability groups (learn to avoid electric shocks)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Uncontrollability groups (no control over shock administration)
Number of subjects: 121

Group type: COMPARATOR
Intervention: No-shock control group
Number of subjects: 121
Study: 85140364

Group type: EXPERIMENTAL
Intervention: Transfer factor specific for hepatitis B (TFdL-H) administered at 15-day intervals over a 6-month period
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Transfer factor specific for hepatitis B (TFdL-H)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Untreated CAH patients
Number of subjects: 10
Study: 35296379

Group type: EXPERIMENTAL
Intervention: Cognitive training plus Taichi exercise
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Multimodal intervention
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Cognitive training
Number of subjects: 153

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 153
Study: 33092320

Group type: EXPERIMENTAL
Intervention: Carn‐βA (2.5 g L‐carnosine plus 2.5 g β‐alanine)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 10
Study: 35078147

Group type: EXPERIMENTAL
Intervention: Mézières method (experimental group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard European treatment protocol for LBP (control group)
Number of subjects: 20
Study: 33138680

Group type: EXPERIMENTAL
Intervention: Chitosan chewing gum
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo chewing gum
Number of subjects: 36
Study: 34637608

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (20 mg) under fasted conditions
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (20 mg) under fed conditions (high-fat diet)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Rivaroxaban test formulation
Number of subjects: 72

Group type: COMPARATOR
Intervention: Rivaroxaban reference formulation (Xarelto)
Number of subjects: 72
Study: 34272343

Group type: EXPERIMENTAL
Intervention: Nasal High Flow (nHF) with 'rescue' CPAP backup
Number of subjects: 754

Group type: COMPARATOR
Intervention: Nasal Continuous Positive Airway Pressure (CPAP)
Number of subjects: 754

Group type: COMPARATOR
Intervention: Nasal High Flow (nHF) as sole primary support
Number of subjects: 754
Study: 32243573

Group type: EXPERIMENTAL
Intervention: O-R toothbrush
Number of subjects: 110

Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 110
Study: 36174434

Group type: EXPERIMENTAL
Intervention: Curcumin + piperine (500 mg daily)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 32460725

Group type: EXPERIMENTAL
Intervention: Elimination Diet (ED)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Healthy Diet
Number of subjects: 162

Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 162
Study: 35838377

Group type: EXPERIMENTAL
Intervention: Climate Schools mental health programme
Number of subjects: 2539

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2539
Study: 32981068

Group type: EXPERIMENTAL
Intervention: Cysteamine cream
Number of subjects: 20

Group type: COMPARATOR
Intervention: Hydroquinone cream
Number of subjects: 20
Study: 32683541

Group type: EXPERIMENTAL
Intervention: Ordered treatment methods based on maximum-likelihood and robust estimation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proposed robust estimation method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extensions for nonmonotonic alternatives
Number of subjects: 0
Study: 35672192

Group type: EXPERIMENTAL
Intervention: One additional educational session in inhaler use
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 64
Study: 33124927

Group type: EXPERIMENTAL
Intervention: mini Child Tourette Syndrome Impairment Scale (mini‐CTIM)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Tic treatment
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Regression models
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Parent assessment
Number of subjects: 61
Study: 32933510

Group type: EXPERIMENTAL
Intervention: Young Women's Health CoOp intervention with additions of PrEP knowledge and adherence
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Stigma and Discrimination (S&D) reduction training for clinic staff
Number of subjects: 900
Study: 36041980

Group type: EXPERIMENTAL
Intervention: Gestational weight gain (GWG) intervention
Number of subjects: 430

Group type: COMPARATOR
Intervention: No GWG intervention (Control)
Number of subjects: 430
Study: 33545022

Group type: EXPERIMENTAL
Intervention: PCV20
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: cPCV7
Number of subjects: 104

Group type: COMPARATOR
Intervention: PCV13
Number of subjects: 104
Study: 34558739

Group type: EXPERIMENTAL
Intervention: Laparoscopic total extraperitoneal repair technique
Number of subjects: 120

Group type: COMPARATOR
Intervention: Lichtenstein hernia repair open technique
Number of subjects: 120
Study: 32706953

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (400 mg twice daily)
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (400 mg twice daily) plus Azithromycin (500 mg once daily for 7 days)
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (alone or with azithromycin)
Number of subjects: 504
Study: 35812431

Group type: EXPERIMENTAL
Intervention: Anemia in HIV-TB coinfected persons
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: TB participants
Number of subjects: 159

Group type: COMPARATOR
Intervention: Non-TB participants
Number of subjects: 159
Study: 34031865

Group type: EXPERIMENTAL
Intervention: Conventional cardiovascular drugs (ACE inhibitors, angiotensin receptor blockers, anticoagulants, acetosalicylic acid, antiarrhythmic drugs, statins)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antithrombotics, pulmonary vasodilators, RAAS‐related drugs, colchicine (ongoing RCTs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long term anti‐atherogenic therapies (statins)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Current cardiovascular drugs
Number of subjects: 0
Study: 32822887

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) - enoxaparin sodium 20 mg (2000 IU) twice a day for 1 week postoperatively
Number of subjects: 400

Group type: COMPARATOR
Intervention: Physical therapy (Control group)
Number of subjects: 400
Study: 36355633

Group type: EXPERIMENTAL
Intervention: Mental health chatbot (XiaoE)
Number of subjects: 148

Group type: COMPARATOR
Intervention: E-book
Number of subjects: 148

Group type: COMPARATOR
Intervention: General chatbot (Xiaoai)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Usability (UMUX-LITE)
Number of subjects: 148
Study: 33538404

Group type: EXPERIMENTAL
Intervention: Ataluren
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 32784157

Group type: EXPERIMENTAL
Intervention: Intratympanic dexamethasone
Number of subjects: 107

Group type: COMPARATOR
Intervention: Isotonic solution (Control)
Number of subjects: 107
Study: 35433220

Group type: EXPERIMENTAL
Intervention: Left Lateral (LL) position
Number of subjects: 253

Group type: COMPARATOR
Intervention: Prone Position (PP)
Number of subjects: 253
Study: 32184153

Group type: EXPERIMENTAL
Intervention: BoNT/A
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: BoNT/B
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: BoNT/C
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: BoNT/F
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 34573862

Group type: EXPERIMENTAL
Intervention: Fecal immunochemical test (FIT) surveillance with annual FIT and colonoscopy if fecal hemoglobin concentration is ≥10 µg/g
Number of subjects: 3788

Group type: COMPARATOR
Intervention: Endoscopic surveillance
Number of subjects: 3788
Study: 33238964

Group type: EXPERIMENTAL
Intervention: Intervention clinics (17 clinics)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Overall risk stratification across 33 clinics
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Front desk identification of patients with back pain
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Rooming process
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Time with clinician
Number of subjects: 33
Study: 35246356

Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) session during breaktime (8 minutes)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Usual breaktime (control)
Number of subjects: 88
Study: 34210943

Group type: EXPERIMENTAL
Intervention: Screening Tool 1
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Screening Tool 2
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Screening Tool 3
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Child Report of Post‐Traumatic Symptoms questionnaire
Number of subjects: 52
Study: 32998732

Group type: EXPERIMENTAL
Intervention: Semaglutide (once-weekly subcutaneous)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Semaglutide (once-daily oral)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparators (including placebo)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35534178

Group type: EXPERIMENTAL
Intervention: GLAUC-STRAT fast tool
Number of subjects: 0
Study: 34237330

Group type: EXPERIMENTAL
Intervention: sRAGE levels
Number of subjects: 6861
Study: 33165005

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks or once weekly with and without topical corticosteroids
Number of subjects: 2632

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2632
Study: 32767806

Group type: EXPERIMENTAL
Intervention: R-CHOP-14
Number of subjects: 71

Group type: COMPARATOR
Intervention: R-CHOP-14/CHASER
Number of subjects: 71
Study: 35428316

Group type: EXPERIMENTAL
Intervention: Combined phenylephrine 1.67% and tropicamide 0.33% microdrops
Number of subjects: 93

Group type: COMPARATOR
Intervention: Standard drops
Number of subjects: 93
Study: 34220306

Group type: COMPARATOR
Intervention: S‐38 position (stretcher bed height 38 ± 1 cm)
Number of subjects: 16
Study: 32772319

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 100
Study: 35247964

Group type: COMPARATOR
Intervention: Low-sodium (3 g/d salt) + placebo
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Medium-sodium (5 g/d salt) + spironolactone (SPL)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Low-sodium (3 g/d salt) + spironolactone (SPL)
Number of subjects: 74
Study: 35167779

Group type: EXPERIMENTAL
Intervention: Sepetaprost 0.002%
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005%
Number of subjects: 196

Group type: COMPARATOR
Intervention: All sepetaprost doses
Number of subjects: 196
Study: 34145564

Group type: EXPERIMENTAL
Intervention: Primary care Intensive Management (PIM)
Number of subjects: 3784

Group type: COMPARATOR
Intervention: Usual primary care
Number of subjects: 3784

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 3784
Study: 32388344

Group type: EXPERIMENTAL
Intervention: Underfed (60% of dietary recommendations)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Overfed (200% of dietary recommendations)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control (100% of dietary recommendations)
Number of subjects: 3
Study: 33881639

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 248

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 248
Study: 33559053

Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg daily for 21 days starting from day 1 in each cycle in addition to platinum-based chemotherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Platinum-based chemotherapy
Number of subjects: 60
Study: 32856781

Group type: EXPERIMENTAL
Intervention: Accredited Healthy Workplace
Number of subjects: 1648

Group type: COMPARATOR
Intervention: Control group (non-accredited corporations)
Number of subjects: 1648
Study: 33779716

Group type: EXPERIMENTAL
Intervention: Multiple Arterial Grafts (MAG)
Number of subjects: 2111

Group type: COMPARATOR
Intervention: Single Arterial Grafts (SAG)
Number of subjects: 2111
Study: 34235737

Group type: EXPERIMENTAL
Intervention: Genomic analyses of common risk variants (SNPs) shared by ASD and ADHD
Number of subjects: 101724

Group type: EXPERIMENTAL
Intervention: Genomic analyses of common risk variants (SNPs) specific to each disorder
Number of subjects: 101724

Group type: EXPERIMENTAL
Intervention: Bidirectional Mendelian randomization analysis
Number of subjects: 101724
Study: 32381110

Group type: EXPERIMENTAL
Intervention: Opposing electroacupuncture (EA) on the healthy side, sham EA on the operated side
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Operated side EA, sham EA on the healthy side
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham EA on both sides
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35920945

Group type: EXPERIMENTAL
Intervention: Cervical spinal cord stimulation (cSCS) for 10-14 consecutive days starting within 3 days of aneurysm rupture
Number of subjects: 12
Study: 32851714

Group type: EXPERIMENTAL
Intervention: Cervical length (CL) measurement < 10 mm at hospital discharge
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Cervical length (CL) measurement < 10 mm up to 2 weeks post discharge
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Cervical length (CL) measurement < 10 mm up to 4 weeks post discharge
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Cervical length (CL) measurement at 8 weeks post discharge
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Cervical length (CL) measurement at 12 weeks post discharge
Number of subjects: 226
Study: 33631742

Group type: EXPERIMENTAL
Intervention: Otago Exercise Program (OEP)
Number of subjects: 172
Study: 32809224

Group type: EXPERIMENTAL
Intervention: B‐cell precursor ALL
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: T‐lineage ALL
Number of subjects: 97
Study: 34168284

Group type: EXPERIMENTAL
Intervention: ixazomib (4 mg, days 1, 8, 15) plus dexamethasone (20 mg, days 1, 8, 15, 22; n = 85)
Number of subjects: 168

Group type: COMPARATOR
Intervention: physician’s choice (dexamethasone ± melphalan, cyclophosphamide, thalidomide, or lenalidomide; n = 83)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: ixazomib–dexamethasone
Number of subjects: 168
Study: 33595198

Group type: EXPERIMENTAL
Intervention: NoiBene programme
Number of subjects: 202
Study: 32539655

Group type: EXPERIMENTAL
Intervention: High-intensity psychosocial intervention
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standardized usual care
Number of subjects: 200
Study: 34463842

Group type: EXPERIMENTAL
Intervention: Monthly ranibizumab
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Monthly ranibizumab with targeted retinal photocoagulation (TRP)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: As-needed ranibizumab and TRP
Number of subjects: 40

Group type: COMPARATOR
Intervention: All cohorts
Number of subjects: 40